close

Simcere Pharmaceutical Group, together with its subsidiaries, engages in the research, development, manufacture, distribution, and marketing of branded generic pharmaceutical products in the People's Republic of China. Its principal products include prescription edaravone injection for the treatment of strokes under the Bicun brand; amoxicillin capsules, dispersible tablets, granules, and injection under the brand Zailin; and generic diclofenac sodium, an anti-inflammatory pain reliever and analgesic drug to treat rheumatoid arthritis and osteoarthritis under the brand Yingtaiqing. The company's products also comprise sustained release implants under the Sinofuan brand for the treatment of cancer; edaravone injection under the Yidasheng brand for the treatment of strokes; anti-diarrhea pharmaceutical under the Biqi brand; cefaclor in dry suspension antibiotics under the Zake brand for the treatment of infections; and a herbal medicine used for the treatment of coughs under the Simcere Kechuanning brand name. In addition, it distributes prescription pharmaceuticals manufactured by independent third parties, including generic alfacalcidol soft capsules under the name Faneng, and generic lentinan injection under the brand Yineng. As of March 31, 2009, it also had 12 product candidates in various stages of development, including treatments for cancer, cerebrovascular diseases, infections, rheumatoid arthritis, nausea, and vomiting associated with chemotherapy. The company manufactures and sells 45 pharmaceuticals products and distributes 3 additional pharmaceuticals that are manufactured by independent third parties under the company's brand names. It has an agreement with Epitomics, Inc. for the co-development and production of humanized RabMAb antibody therapeutics for tumors. Simcere Pharmaceutical Group was founded in 1995 and is headquartered in Nanjing, the People's Republic of China.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	8.57
Volume	146090
Volume Avg	58254
52 Week High	13.48
52 Week Low	7.12
PE	17.43
PE (group average)	N/A
EPS Year	0.51
EPS change Q/Q	-50%
EPS change Q/Q Yr ago	33.33%
EPS change Q/Q next Q est	-71.43%
EPS change Y/Y	100%
REV change Q/Q	-17.97%
REV change Q/Q Yr ago	5.08%
EPS next Q est	0.14
EPS next Y est	0.45
Divident Annual	0.00
Dividend Yield	0%